Identifying the Best Treatments

for Patients with Rare Cancers

Rare cancers present special challenges for patients and their physicians.  Relative to more commonly occurring cancer types, fewer clinical trials are conducted and fewer new drugs are developed.  Therefore, fewer chemotherapy options exist.

Further, because most oncologists have limited experience in treating rare cancer types, the task of choosing effective therapy becomes even more uncertain.

Here is where Precision Functional Cancer Profiling becomes especially valuable.  Instead of accepting unproven treatments and/or blindly entering an investigational clinical trial, patients can use Precision Functional Cancer Profiling to pinpoint the most highly promising, personalized chemotherapy treatment.  

Precision Functional Cancer Profiling shows objectively how a wide range of drugs in all classes - standard cytotoxic, immunologic, kinase targeted, and anti-angiogenic - work against each patient’s own, living cancer cells.

Armed with this crucial information it is possible to select the best treatment regimen for each patient without resorting to guesswork.

For those patients who are determined to enter a clinical trial, knowing in advance which drugs work best against his or her own cancer cells allows them to choose a cliinical trial that specifically involves those drugs.

Precision Functional Cancer Profiling takes much of the uncertainty out of choosing effective treatments for patients with rare cancer types.